Cancer produces protein that reduces Alzheimer’s plaques in rats, Chinese study shows

Pesquisadores have observed for decades that cancer and Alzheimer disease rarely appear in the same person. A study published in January provided experimental evidence to explain this inverse relationship. Células tumors produce a protein that circulates through the blood, reaches the brain and helps reduce protein deposits associated with dementia.

The work used modified mice to develop characteristics of Alzheimer. Scientists transplanted human tumors into these animals. The results showed fewer plaques in the brain tissue of mice with cancer. Além In addition, their performance in memory tests has clearly improved.

The study was conducted by a team from Universidade of Ciência and Tecnologia Huazhong, at China. The researchers published the findings in the journal Cell. The investigation lasted years and involved detailed analysis of proteins secreted by tumors.

Proteína cystatin C crosses blood-brain barrier and activates brain defense

The protein responsible for the protective effect is cystatin C. Ela is released by cancer cells and travels through the bloodstream. Depois, the molecule can cross the barrier that protects the brain. Inside brain tissue, cystatin C binds to beta-amyloid oligomers, which form the toxic plaques typical of Alzheimer.

Essa binding activates the TREM2 receptor on microglial cells. Microglia function as the brain’s immune system. Quando activated by the cystatin C pathway, it starts to degrade the plaques already formed. The process not only prevents the formation of new deposits but also removes existing ones.

• The transplanted tumors were from human lung, prostate and colon.
• Cystatin C was identified after analyzing all proteins secreted by tumor cells.
• Camundongos with cancer had much lower burden of amyloid plaques in the brain.
• Activation of TREM2 in microglia increased phagocytosis of toxic plaques.
• Behavioral Testes showed recovery in memory capacity and spatial navigation.

The authors tested the isolated protein. Animais who received only purified cystatin C had similar results to the tumor group. Isso indicates that the effect does not depend on the presence of the cancer itself, but on the action of this specific molecule.

Epidemiological Observação gains molecular basis in animal model

The inverse correlation between cancer and Alzheimer has been known since the 2000s. Metanálises with millions of patients showed a reduction of about 11% in the risk of Alzheimer among those diagnosed with cancer. The new study offers a concrete mechanism to explain the phenomenon.

The researchers transplanted three different types of human tumors into mice that already had a genetic predisposition to accumulate beta-amyloid. Animals with tumors did not develop brain plaques to the same level as the control group. The difference appeared both in the quantity and distribution of deposits.

The team followed the mice for prolonged periods. Eles measured protein levels in blood and brain tissue. Testes repeated behavioral tests confirmed that the animals with cancer maintained better cognitive function. Eles found platforms faster in water mazes and had greater learning capacity.

Cistatina C binds toxic oligomers and recruits microglia

Cystatin C does not act alone. Ela binds directly to the small clumps of beta-amyloid that are considered the most toxic. Essa interaction exposes signals that the TREM2 receptor recognizes. TREM2, in turn, activates microglial cells so that they engulf and degrade plaques.

Quando scientists blocked the cystatin C pathway in experiments, the protective effect disappeared. Plaques accumulated again and cognitive performance worsened. Essa reversal confirmed that the tumor protein is the key link in the mechanism.

The discovery is relevant because microglia in brains with Alzheimer are usually in a dysfunctional state. Ela loses the ability to clear protein waste. Cystatin C appears to restore part of this function by specifically activating TREM2.

Estudo reinforces the importance of investigating relationships between diseases

The work does not suggest that having cancer is beneficial. The authors emphasize that cancer poses serious health risks. Eles only highlight that certain tumor processes produce unexpected side effects in the brain. Essa observation opens a window to better understand the biology of Alzheimer.

Alzheimer disease affects millions of people around the world. Ainda There is no treatment that definitively interrupts the accumulation of plaques and neuronal death. Qualquer clue about factors that naturally reduce protein deposits attracts attention from the scientific community.

Previous Pesquisas had already shown that cystatin C can influence amyloid formation. The Chinese study advances by connecting the protein secreted by peripheral tumors with immune activation in the brain. The pathway involves both direct binding to oligomers and the recruitment of defense cells.

Leia Tambem

Romantic comedies and mysteries arrive on Netflix in June with Office Passion and Oasis

Uruguay announces squad list for the 2026 World Cup with six Brazilian football players

When does the 2026 World Cup start? Date, time, first game and opening ceremony

The mice used were established models of Alzheimer. Eles accumulate beta-amyloid excessively due to genetic modifications. Mesmo in these animals with high toxic protein load, the presence of peripheral tumors significantly reduced the pathology.

Experimentos with isolated protein pave the way for future therapies

Depois To identify cystatin C as the key factor, the team administered the purified protein directly to mice with Alzheimer. The results were consistent. Houve plaque reduction and improvement in cognitive tests without the need to induce tumors.

Essa approach is important because it avoids the risks associated with cancer. The researchers now plan to test variations of the molecule and different doses. Eles also want to understand whether cystatin C affects other proteins involved in Alzheimer, such as tau, which forms tangles inside neurons.

The blood-brain barrier represents a challenge for many therapies. The fact that cystatin C can cross it naturally suggests that it has interesting properties for drug development. Ainda therefore, the authors caution that the data is limited to animal models.

Translation to humans will require careful clinical studies. Diferenças in metabolism, immune response and disease progression across species need to be considered. Mesmo thus the finding represents a new perspective on how the peripheral immune system may influence the brain.

Equipe analyzed multiple tumor types to confirm the mechanism

Researchers did not limit themselves to a single type of cancer. Eles used cells from lung, prostate and colon tumors. In all cases, the protective effect against Alzheimer plaques appeared. Isso suggests that cystatin C secretion may be a common feature of several cancers.

Proteomic analysis revealed that cystatin C was the only molecule consistently elevated in animals with tumors and associated with amyloid reduction. Outras secreted proteins did not produce the same impact when tested alone.

Behavioral tests included tasks assessing object recognition memory, spatial memory, and associative learning ability. In all of them, the groups treated with cystatin C or with tumors had higher scores than the control group without intervention.

Plaque reduction was measured by imaging techniques and biochemical analyzes of brain tissue. The researchers quantified both the number and size of amyloid deposits. The difference between groups was statistically significant.

Resultados fuels debate about connections between cancer and neurodegeneration

The relationship between cancer and Alzheimer is complex. Enquanto some studies show protection against dementia in cancer survivors, others point to shared risks in certain molecular pathways. The new work focuses specifically on protection against amyloid pathology.

Especialistas consider the finding relevant because it directs attention to the role of microglia and TREM2. Mutação in the TREM2 gene is already known as a risk factor for Alzheimer. Ativar this receptor in a controlled manner could become a therapeutic strategy.

For now, the data reinforces the need for more research. The authors plan to investigate whether elevated cystatin C levels in humans with a history of cancer correlate with lower imaging-detectable brain plaque burden. Eles also wants to test whether the protein can be used preventively or in the early stages of the disease.

The study was published on January 22, 2026. Desde then, other scientific outlets commented on the findings. Nature highlighted the work in a report that summarizes the molecular mechanism.

Chinese researchers continue the series of experiments. Próximos steps include testing cystatin C in more advanced models of Alzheimer that also include tau pathology. Eles also intends to evaluate possible long-term side effects of increasing the protein.